170 related articles for article (PubMed ID: 29522315)
21. Novel lactate dehydrogenase inhibitors with in vivo efficacy against Cryptosporidium parvum.
Li K; Nader SM; Zhang X; Ray BC; Kim CY; Das A; Witola WH
PLoS Pathog; 2019 Jul; 15(7):e1007953. PubMed ID: 31356619
[TBL] [Abstract][Full Text] [Related]
22. 7-cyclopentyl-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d] pyrimidin-4-ylamine inhibits the proliferation and migration of vascular smooth muscle cells by suppressing ERK and Akt pathways.
Seo HH; Kim SW; Lee CY; Lim KH; Lee J; Lim S; Lee S; Hwang KC
Eur J Pharmacol; 2017 Mar; 798():35-42. PubMed ID: 28185804
[TBL] [Abstract][Full Text] [Related]
23. Defining Stage-Specific Activity of Potent New Inhibitors of Cryptosporidium parvum Growth
Funkhouser-Jones LJ; Ravindran S; Sibley LD
mBio; 2020 Mar; 11(2):. PubMed ID: 32127445
[No Abstract] [Full Text] [Related]
24. Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy.
Hulverson MA; Vinayak S; Choi R; Schaefer DA; Castellanos-Gonzalez A; Vidadala RSR; Brooks CF; Herbert GT; Betzer DP; Whitman GR; Sparks HN; Arnold SLM; Rivas KL; Barrett LK; White AC; Maly DJ; Riggs MW; Striepen B; Van Voorhis WC; Ojo KK
J Infect Dis; 2017 Apr; 215(8):1275-1284. PubMed ID: 28329187
[TBL] [Abstract][Full Text] [Related]
25. N(7)-substituted-5-aryl-pyrrolo[2,3-d]pyrimidines represent a versatile class of potent inhibitors of the tyrosine kinase c-Src.
Altmann E; Widler L; Missbach M
Mini Rev Med Chem; 2002 Jun; 2(3):201-8. PubMed ID: 12370062
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and biological evaluation of a series of novel pyrrolo[2,3-d]pyrimidin/pyrazolo[3,4-d]pyrimidin-4-amine derivatives as FGFRs-dominant multi-target receptor tyrosine kinase inhibitors for the treatment of gastric cancer.
Wu X; Liu Z; Gan C; Wei W; Zhang Q; Liu H; Que H; Su X; Yue L; He H; Ouyang L; Ye T
Bioorg Chem; 2022 Oct; 127():105965. PubMed ID: 35759882
[TBL] [Abstract][Full Text] [Related]
27. Substituted pyrrolo[2,3-d]pyrimidines as Cryptosporidium hominis thymidylate synthase inhibitors.
Kumar VP; Frey KM; Wang Y; Jain HK; Gangjee A; Anderson KS
Bioorg Med Chem Lett; 2013 Oct; 23(19):5426-8. PubMed ID: 23927969
[TBL] [Abstract][Full Text] [Related]
28. Novel 6-substituted benzoyl and non-benzoyl straight chain pyrrolo[2,3-d]pyrimidines as potential antitumor agents with multitargeted inhibition of TS, GARFTase and AICARFTase.
Xing R; Zhang H; Yuan J; Zhang K; Li L; Guo H; Zhao L; Zhang C; Li S; Gao T; Liu Y; Wang L
Eur J Med Chem; 2017 Oct; 139():531-541. PubMed ID: 28830032
[TBL] [Abstract][Full Text] [Related]
29. Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck II.
Burchat AF; Calderwood DJ; Hirst GC; Holman NJ; Johnston DN; Munschauer R; Rafferty P; Tometzki GB
Bioorg Med Chem Lett; 2000 Oct; 10(19):2171-4. PubMed ID: 11012022
[TBL] [Abstract][Full Text] [Related]
30. Identification of
Zhu Y; Ma Y; Zu W; Song J; Wang H; Zhong Y; Li H; Zhang Y; Gao Q; Kong B; Xu J; Jiang F; Wang X; Li S; Liu C; Liu H; Lu T; Chen Y
J Med Chem; 2020 Jul; 63(13):6748-6773. PubMed ID: 32479083
[TBL] [Abstract][Full Text] [Related]
31. Potent and selective EGFR inhibitors based on 5-aryl-7H-pyrrolopyrimidin-4-amines.
Reiersølmoen AC; Aarhus TI; Eckelt S; Nørsett KG; Sundby E; Hoff BH
Bioorg Chem; 2019 Jul; 88():102918. PubMed ID: 30999245
[TBL] [Abstract][Full Text] [Related]
32. 7-Pyrrolidinyl- and 7-piperidinyl-5-aryl-pyrrolo[2,3-d]pyrimidines--potent inhibitors of the tyrosine kinase c-Src.
Altmann E; Missbach M; Green J; Susa M; Wagenknecht HA; Widler L
Bioorg Med Chem Lett; 2001 Mar; 11(6):853-6. PubMed ID: 11277536
[TBL] [Abstract][Full Text] [Related]
33. Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1.
Larson ET; Ojo KK; Murphy RC; Johnson SM; Zhang Z; Kim JE; Leibly DJ; Fox AM; Reid MC; Dale EJ; Perera BG; Kim J; Hewitt SN; Hol WG; Verlinde CL; Fan E; Van Voorhis WC; Maly DJ; Merritt EA
J Med Chem; 2012 Mar; 55(6):2803-10. PubMed ID: 22369268
[TBL] [Abstract][Full Text] [Related]
34. From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer.
Zhang CH; Chen K; Jiao Y; Li LL; Li YP; Zhang RJ; Zheng MW; Zhong L; Huang SZ; Song CL; Lin WT; Yang J; Xiang R; Peng B; Han JH; Lu GW; Wei YQ; Yang SY
J Med Chem; 2016 Nov; 59(21):9788-9805. PubMed ID: 27739679
[TBL] [Abstract][Full Text] [Related]
35. Activity of 6-aryl-pyrrolo[2,3-d]pyrimidine-4-amines to Tetrahymena.
Kaspersen SJ; Sundby E; Charnock C; Hoff BH
Bioorg Chem; 2012 Oct; 44():35-41. PubMed ID: 22832269
[TBL] [Abstract][Full Text] [Related]
36. Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1.
Zhang Z; Ojo KK; Johnson SM; Larson ET; He P; Geiger JA; Castellanos-Gonzalez A; White AC; Parsons M; Merritt EA; Maly DJ; Verlinde CL; Van Voorhis WC; Fan E
Bioorg Med Chem Lett; 2012 Aug; 22(16):5264-7. PubMed ID: 22795629
[TBL] [Abstract][Full Text] [Related]
37. Optimizing Pyrazolopyrimidine Inhibitors of Calcium Dependent Protein Kinase 1 for Treatment of Acute and Chronic Toxoplasmosis.
Janetka JW; Hopper AT; Yang Z; Barks J; Dhason MS; Wang Q; Sibley LD
J Med Chem; 2020 Jun; 63(11):6144-6163. PubMed ID: 32420739
[TBL] [Abstract][Full Text] [Related]
38. Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I.
Arnold LD; Calderwood DJ; Dixon RW; Johnston DN; Kamens JS; Munschauer R; Rafferty P; Ratnofsky SE
Bioorg Med Chem Lett; 2000 Oct; 10(19):2167-70. PubMed ID: 11012021
[TBL] [Abstract][Full Text] [Related]
39. Dicyclic and tricyclic diaminopyrimidine derivatives as potent inhibitors of Cryptosporidium parvum dihydrofolate reductase: structure-activity and structure-selectivity correlations.
Nelson RG; Rosowsky A
Antimicrob Agents Chemother; 2001 Dec; 45(12):3293-303. PubMed ID: 11709300
[TBL] [Abstract][Full Text] [Related]
40. Neutral sphingomyelinase 2 inhibitors based on the pyrazolo[1,5-a]pyrimidin-3-amine scaffold.
Novotna K; Thomas AG; Stepanek O; Murphy B; Hin N; Skacel J; Mueller L; Tenora L; Pal A; Alt J; Wu Y; Paule J; Rais R; Slusher BS; Tsukamoto T
Eur J Med Chem; 2023 Nov; 259():115674. PubMed ID: 37536209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
